Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells 78,334 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now owns 81,993 shares of the company's stock, valued at $1,124,943.96. This represents a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The shares were sold at an average price of $15.00, for a total transaction of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00.

NeuroPace Price Performance

Shares of NASDAQ NPCE traded up $0.39 during mid-day trading on Friday, reaching $12.95. 134,520 shares of the company were exchanged, compared to its average volume of 117,116. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $16.88. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The stock has a market capitalization of $386.53 million, a PE ratio of -12.95 and a beta of 2.05. The company's 50 day moving average price is $12.69 and its 200 day moving average price is $9.64.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NPCE. UBS Group initiated coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They issued a "buy" rating and a $17.00 price objective for the company. Wells Fargo & Company boosted their price target on shares of NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research report on Tuesday, December 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.80.

Institutional Trading of NeuroPace

A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after purchasing an additional 2,279 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in NeuroPace in the fourth quarter worth $29,000. Financial Advocates Investment Management lifted its stake in NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company's stock worth $125,000 after purchasing an additional 3,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in NeuroPace by 21.2% in the fourth quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock worth $328,000 after purchasing an additional 5,133 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in NeuroPace by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock worth $3,615,000 after purchasing an additional 5,781 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.